Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis – impact of radiochemistry on pharmacokinetics

Gezim Bala, Maxine Crauwels, Anneleen Blykers, Isabel Remory, Andrea L. J. Marschall, Stefan Dübel, Laurent Dumas, Alexis Broisat, Charlotte Martin, Steven Ballet,

Biological Chemistry · 2018 · 32 citations · 27 references

Concepts

TL;DR

Let's parse content. Background: "Abstract Radiolabeling of nanobodies with radiometals by chelation has the advantage of being simple, fast and easy to implement in clinical routine." So background: radiolabeling of nanobodies with radiometals by chelation is simple, fast, easy for clinical routine. Purpose: lines labeled Purpose: first line: "In this study, we validated 68 Ga/ 111 In-labeled anti-VCAM-1 nanobodies as potential radiometal-based tracers for molecular imaging of atherosclerosis." Also second Purpose: "We further investigated the impact of different radiolabeling strategies on the in vivo biodistribution of nanobody-based tracers." So purpose: validate 68Ga/111In anti-VCAM-1 nanobodies as tracers for atherosclerosis imaging and investigate impact of radiolabeling strategies on biodistribution. Mechanism: lines labeled Mechanism: same as Purpose lines.

Abstract

Abstract Radiolabeling of nanobodies with radiometals by chelation has the advantage of being simple, fast and easy to implement in clinical routine. In this study, we validated 68 Ga/ 111 In-labeled anti-VCAM-1 nanobodies as potential radiometal-based tracers for molecular imaging of atherosclerosis. Both showed specific targeting of atherosclerotic lesions in ApoE −/− mice. Nevertheless, uptake in lesions and constitutively VCAM-1 expressing organs was lower than previously reported for the 99m Tc-labeled analog. We further investigated the impact of different radiolabeling strategies on the in vivo biodistribution of nanobody-based tracers. Comparison of the pharmacokinetics between 68 Ga-, 18 F-, 111 In- and 99m Tc-labeled anti-VCAM-1 nanobodies showed highest specific uptake for 99m Tc-nanobody at all time-points, followed by the 68 Ga-, 111 In- and 18 F-labeled tracer. No correlation was found with the estimated number of radioisotopes per nanobody, and mimicking specific activity of other radiolabeling methods did not result in an analogous biodistribution. We also demonstrated specificity of the tracer using mice with a VCAM-1 knocked-down phenotype, while showing for the first time the in vivo visualization of a protein knock-down using intrabodies. Conclusively, the chosen radiochemistry does have an important impact on the biodistribution of nanobodies, in particular on the specific targeting, but differences are not purely due to the tracer’s specific activity.

References

27